- Rett Syndrome, a rare genetic neurological disorder that affects brain development, primarily in females, is witnessing growing awareness and research attention across Europe. The increasing focus on early diagnosis, gene therapy innovation, and supportive care infrastructure is boosting market activity in both clinical and commercial segments
- The escalating demand for novel therapeutic approaches is primarily fueled by the limited efficacy of current symptomatic treatments, rising patient advocacy, and expanded research funding by governments and private organizations in Europe
- Germany dominated the Europe Rett syndrome market in 2024, owing to robust healthcare infrastructure, increased funding for rare disease research, and the early adoption of innovative treatment approaches such as gene and enzyme therapies
- France is expected to witness the highest CAGR in the Europe Rett syndrome market during the forecast period, continuing to make considerable strides in rare disease management due to strong government-backed initiatives such as the French National Plan for Rare Diseases
- The classic Rett syndrome segment dominated the Europe Rett Syndrome market with a market share of 71.3% in 2024, owing to its higher prevalence and earlier diagnosis. Increased clinical awareness, availability of genetic testing for MECP2 mutations, and focused research on managing classic symptoms have contributed to the segment’s dominance
